lonza
Lonza to buy US biologics site from Roche for US$1.2 billion
Swiss contract drug manufacturer Lonza said on Wednesday (Mar 20) it signed an agreement to acquire the Genentech manufacturing facility in Vacaville, California, from drugmaker Roche for US$1.2 billi...
Lonza's first-half core Ebitda gains 16.5%
Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5 per cent on strong demand from biopharmaceutical companies.
Lonza plans new production line to make Moderna Covid-19 vaccine ingredients
[ZURICH] Swiss contract drug manufacturer Lonza said on Wednesday that a new production line in the Netherlands will produce ingredients for Moderna's Covid-19 vaccine, part of the US drugmaker's plan...
Bain, Cinven buy Lonza Specialty Ingredients in S$6.25b deal
[ZURICH] Bain Capital and Cinven are acquiring Lonza's Specialty Ingredients division in a deal worth S$6.25 billion, the Swiss contract drug maker said on Monday, as it focuses on its faster-growing ...
Corporate digest
CHEMICALS and biotech company Lonza Group will buy a sterile drug product fill-and-finish facility in Stein, Switzerland, from Novartis. Lonza, which has a secondary listing on the Singapore Exchange,...
Lonza to buy drug production facility in Switzerland from Novartis
CHEMICALS and biotech company Lonza Group will purchase a sterile drug product fill-and-finish facility in Stein, Switzerland, from Novartis.
Lonza in joint venture to develop biotherapeutic products
SWISS biotech company Lonza has entered into an equal joint venture (JV) with Danish bioscience company Chr Hansen Holding to develop live biotherapeutic products (LBP) for pharma and biotech customer...
Lonza enters 90m euro JV to develop biotherapeutic products
SWISS biotech company Lonza has entered into a 50/50 joint venture (JV) with Danish bioscience company Chr. Hansen to invest about 90 million euros (S$136.6 million) over three years to develop live b...
Lonza first-half profit beats estimates, prompting asset review
[FRANKFURT] Lonza Group, the world's largest custom maker of drug-ingredients, reported first-half profit that beat analyst estimates and said it will review its portfolio to boost profitability furth...
